Authors

Bridging the Gap: A Large Pharma Blueprint

Five steps for organizations in bringing enterprise-level strategies to life.

From Advantage to Essential: How Daily Data & AI Alerts Transform Commercial Functions

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

Elevating and De-Risking Your Drug Portfolio Strategy With AI

Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

From ‘Pilotitis’ to Productivity: Reimagining AI’s Role in R&D

A blueprint for how companies can move from isolated pilots toward effective AI implementation.

The Evolution of Patient Assistance Programs: A Holistic, Person-Centered Approach

Unlocking the Next Frontier in AI-Driven Drug Discovery

The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations

An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.

Driving Field Excellence with AI-Enhanced Rep Support

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

The Three Pillars of Pharma’s New Commercial Model

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Nitrosamine Detection in Pharmaceuticals: A Faster, Greener, and More Effective Approach

How to Overcome Market Access Hurdles for Inpatient Drug Launches

FDA’s New Accelerated Approval Draft Guidance

What biopharma companies need to know about this evolving regulatory pathway.

De-Risking Clinical Development: Strategic Multipliers in Global Trials

Effective governance models in CRO-sponsor partnerships: Lessons from the Bayer-Parexel collaboration

Beyond Approval: Why Your Oncology Label Determines Commercial Success

The stakes have never been higher.

The Recipe for Relief: Overcoming Industry Pain Points

Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.

Effective governance models in CRO-sponsor partnerships: Lessons from the Bayer-Parexel collaboration

Proactive Engagement: How AI-Driven Alerts are Transforming HCP Outreach

The benefits for brand teams in bolstering their rapid-response capability.

Survey: How Have the Tariffs & Trade Policy Affected the Pharmaceutical Industry?

Complete this survey to illustrate how new tariffs and trade policy have impacted you and your organization.

Coaching Flag Football—And Guiding a Biotech Through Commercialization

Useful tips and parallels for staying in the game following a complete response letter.

Approaching Agentic AI Strategically: Life Sciences Data Utilization

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

Optimizing next-generation sequencing for precision oncology trials

This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.

Executive Presence: The Leadership Edge Pharma Leaders Can't Afford to Overlook

Unlock the secrets of executive presence in pharma to inspire confidence, influence decisions, and elevate your leadership impact.

Biopharma Needs a Health System Strategy to Secure Optimal Market Access

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

From Lab to Market: Tracking Today’s Shifting Pathways for Biotech

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

Fair Market Value vs. Current Market Leverage

How pharmaceutical manufacturers should consider their Fair Market Value cost assessment compared to their negotiation leverage when contracting for distribution services